Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer

Nicholas G Nickols¹, Sonny Tsai², Nathanael Kane³, Samantha Tran², Leila Ghayouri², Silvia Diaz-Perez³, May Thein⁴, Nancy Anderson-Berman⁴, Jeanie Eason⁵, Amar U Kishan⁶, Michael L Steinberg⁶, Robert E Reiter⁷, Steve P Lee⁴, Greg E Gin⁴, Robert Kwon⁴, Michael G Chang⁵, Hann-Hsiang Chao⁵, Abhiskek A Solanki⁸, Rachael Sexton⁹, Michael Lewis², William Lorentz³, Michael K Cheung³, Diana L Gage³, Sai Duriseti³, Luca Valle³, Gholam Berenji², William J Aronson¹⁰, Isla P Garraway¹⁰, Matthew B Rettig¹¹

Affiliations

¹ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: nicholas.nickols@va.gov.
² VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
³ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁴ VA Long Beach Healthcare System, Long Beach, CA, USA.
⁵ Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
⁶ Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁷ Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁸ Department of Radiation Oncology, Loyola University and Hines VA Medical Center, Chicago, IL, USA.
⁹ Cancer Research and Biostatistics, Seattle, WA, USA.
¹⁰ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
¹¹ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

PMID: 38490853
PMCID: PMC12363338
DOI: 10.1016/j.eururo.2024.02.008

Clinical Trial

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer

Nicholas G Nickols et al. Eur Urol. 2024 Aug.

. 2024 Aug;86(2):190-193.

doi: 10.1016/j.eururo.2024.02.008. Epub 2024 Mar 14.

Authors

Affiliations

¹ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: nicholas.nickols@va.gov.
² VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
³ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁴ VA Long Beach Healthcare System, Long Beach, CA, USA.
⁵ Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
⁶ Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁷ Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁸ Department of Radiation Oncology, Loyola University and Hines VA Medical Center, Chicago, IL, USA.
⁹ Cancer Research and Biostatistics, Seattle, WA, USA.
¹⁰ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
¹¹ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

PMID: 38490853
PMCID: PMC12363338
DOI: 10.1016/j.eururo.2024.02.008

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Nicholas G. Nickols has received grants from Janssen, Lantheus, and Bayer, and personal fees from PrimeFour outside the submitted work. Matthew B. Rettig has received speaking honoraria or consulting fees from Ambrx, Amgen, Clovis Oncology, Roivant, NKimmune, Johnson & Johnson, and Bayer; and speaking honoraria from Janssen Oncology, Genomic Health, ImaginAb, Bayer Schering Pharma, and Pfizer outside the submitted work. Amar U. Kishan has received personal fees from ViewRay, Varian Medical Systems, and Boston Scientific; speaking honoraria, consulting fees, and research support from Varian Medical Systems, ViewRay, and Intelligent Automation; grants from Janssen and Point Biopharma; and research funding from ViewRay outside the submitted work. Michael L. Steinberg has received consulting fees from ViewRay outside the submitted work. The remaining authors have nothing to disclose.

Figures

**Fig. 1 –**
(A) Swimmer plot showing time on therapy and events: initial 6 months of active therapy, time off therapy but before testosterone recovery, time after testosterone recovery, and time after initiation of salvage therapy. PSA progression and metastatic progression events are indicated, as well as cases with a positive primary endpoint. Kaplan-Meier curves for (B) biochemical (PSA) PFS, (C) rPFS, and (D) time to salvage therapy. Dashes represent censored cases. There were no deaths. All patients with PSA progression underwent restaging with prostate-specific membrane antigen positron emission tomography/computed tomography, and systemic therapy was reinitiated after metastatic progression. PFS = progression-free survival; PSA = prostate-specific antigen; rPFS = radiographic PFS.

See this image and copyright information in PMC

References

1. Connor MJ, Smith A, Miah S, et al. Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: a systematic review of prospective clinical trials. Eur Urol Oncol 2020;3:582–93. 10.1016/j.euo.2020.07.004. - DOI - PubMed
1. O’Shaughnessy MJ, McBride SM, Vargas HA, et al. A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology 2017;102:164–72. 10.1016/j.urology.2016.10.044. - DOI - PMC - PubMed
1. Reyes DK, Trock BJ, Tran PT, et al. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Med Oncol 2022;39:63. 10.1007/s12032-022-01662-7. - DOI - PubMed
1. Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol 2023;24:443–56. 10.1016/S1470-2045(23)00148-1. - DOI - PMC - PubMed
1. McKay RR, Xie W, Ye H, et al. Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer. J Urol 2021;206:80–7. 10.1097/JU.0000000000001702. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer

Affiliations

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer

Authors

Affiliations

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical